期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
轻度或中度慢性肾脏疾病对冠状动脉再狭窄发生率的影响:来自PRESTO试验的结果
1
作者 Best P.J.M. berger p.b. +1 位作者 Davis B.R. 杜媛 《世界核心医学期刊文摘(心脏病学分册)》 2005年第3期53-54,共2页
The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Re... The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance(CrCl)(< 60, 60 to 89, >89ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization(TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, therewas no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group(2.2%, 1.2%, 0.8%; p >0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis(< 50%) was not increased with CKD(32%, 32%, 37%; p=0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality. 展开更多
关键词 慢性肾脏疾病 PRESTO 再狭窄发生率 慢性肾病 靶血管血运重建 肌酐清除率 晚期死亡 曲尼司特 肌酐水平 混杂变量
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部